10x Genomics (TXG) risk factors, FY2024 10-K

Risks related to our business and industry

1. 01Our operating results have in the past fluctuated significantly and may continue to fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
2. 02Our business is significantly dependent on researchers who rely heavily on government funding, including NIH grants, and any reduction in, modification of the terms of or delay in such funding could adversely affect our sales and financial performance
3. 03Our business currently depends significantly on research and development spending by research institutions, a reduction in which could limit demand for our products and materially and adversely affect our business and operating results
4. 04Our industry is highly competitive. If we fail to compete effectively, our business and operating results will suffer
5. 05In addition, other competitors are in the process of developing novel technologies which may lead to products that rival or replace our products. We expect new competitors to continue to emerge and the intensity of competition with both new and existing competitors to continue to increase
6. 06Price reductions, discounting or future price changes may negatively impact our financial results if we are unable to achieve offsetting benefits
7. 07Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business
8. 08Our future success is dependent upon our ability to increase penetration in our existing customer segments
9. 09Our past or future efforts to maintain and increase the effectiveness of our commercial organization may not succeed
10. 10The size of the market for our solutions may be smaller than estimated and new opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our solutions
11. 11estimates and assumptions, including the assumption that government or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our solutions
12. 12Our products generate large-scale complex data which requires advanced analytics to interpret
13. 13Our failure to effectively manage product transitions or accurately forecast customer demand could result in excess or obsolete inventory and resulting charges
14. 14again lead us, to carry higher inventory. Further, differences in purchasing patterns across our customer base could negatively impact our ability to accurately forecast demand
15. 15We may be unable to consistently manufacture our instruments and consumables to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level
16. 16An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs will have a negative impact and may have a material adverse effect on our business, financial condition and results of operations
17. 17Undetected errors or defects in our solutions could harm our reputation and decrease market acceptance of our solutions
18. 18We are significantly dependent upon revenue generated from the sale of our Chromium solutions, and in particular our Universal Gene Expression solutions
19. 19Doing business internationally creates operational and financial risks for our business
20. 20Our business in China subjects us to unique commercial, operational, competitive and regulatory risks
21. 21We and our customers are dependent on single source and sole source suppliers for some of the equipment, components and materials used in our products and in conjunction with our products and the loss of any of these suppliers could harm our business
22. 22Certain disruptions in supply of, and changes in the competitive environment for, raw materials integral to the manufacturing of our products may adversely affect our profitability
23. 23Our limited operating history and fluctuations in revenue make it difficult to evaluate our future prospects and the risks and challenges we may encounter
24. 24If our existing and new products or new versions of existing products fail to achieve and sustain sufficient scientific acceptance, we will not generate expected revenue and our prospects may be harmed
25. 25If we do not sustain or successfully manage our growth and anticipated growth, our business and prospects will be harmed
26. 26We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of our capital investment requirements or profitability
27. 27Our results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates
28. 28We depend on our key personnel and other highly qualified personnel, and if we are unable to recruit, train, retain and ensure the health and safety of our personnel, we may not achieve our goals
29. 29If our facilities or our third-party manufacturers’ facilities become unavailable or inoperable, our research and development programs could be adversely impacted and manufacturing of our instruments and consumables could be interrupted
30. 30and the equipment we and our third-party manufacturers use to manufacture our instruments and consumables and that we use in our research and development programs would be costly to replace and could require substantial lead times to repair or replace
31. 31We rely exclusively on commercial carriers to transport our products, including perishable consumables, to our customers in a timely and cost-efficient manner and if delivery of our products is disrupted, our business will be harmed
32. 32Costs or other factors related to our facilities and real estate could adversely impact our business
33. 33If we fail to offer high-quality customer service, our business and reputation could suffer
34. 34The number of our customers has grown significantly and such growth, as well as any future growth, will put additional pressure on our customer service organization. We may be unable to hire qualified staff quickly enough or to the extent necessary to accommodate increases in demand
35. 35Investments and acquisitions could disrupt our business, cause dilution to our stockholders and otherwise harm our business
36. 36Seasonality may cause fluctuations in our revenue and results of operations
37. 37Our reliance on distributors for sales of our products in certain geographies outside of the United States could limit or prevent us from selling our products and impact our revenue
38. 38Uncertain economic or social conditions may adversely impact demand for our products or cause our customers, vendors and suppliers to suffer financial hardship, which could adversely impact our business
39. 39Inflationary pressures, and changes in foreign currency exchange rates, interest rates and market value of our investments, including marketable securities, could have a significant effect on results
40. 40We use artificial intelligence (“AI”), machine learning and automated decision-making technologies (collectively, “AI Technologies”) in our business and are making targeted investments in this area
41. 41If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired
42. 42The illegal distribution and sale by third parties of stolen, counterfeit or unfit versions of our products could have a negative impact on our reputation and business
43. 43The investment of marketable securities is subject to risks which may cause losses and affect the liquidity of these investments
44. 44Indebtedness may impair our financial and operating flexibility

Risks related to our regulatory environment and taxation

1. 45We are subject to risks related to taxation in multiple jurisdictions and changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
2. 46Our ability to use net operating losses to offset future taxable income may be subject to certain limitations
3. 47Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing could reduce demand for our products

Risks related to our intellectual property, information technology and data security

1. 48Our success will depend on our ability to obtain, maintain and protect our intellectual property rights
2. 49If we cannot successfully enforce our intellectual property rights, the commercial value of our products and technologies will be adversely affected and our competitive position may be harmed
3. 50We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights
4. 51We depend on certain intellectual property rights that are licensed to us. We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture and/or commercialize our current and/or future products or technologies
5. 52In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information that is not patentable or that we elect not to patent
6. 53We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors
7. 54Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
8. 55our ability to obtain new patents or to enforce patents that we own or that we might obtain or license in the future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition
9. 56areas. It is possible that we will not be able to enforce our intellectual property rights against third parties that misappropriate our proprietary technology in those countries
10. 57Intellectual property rights do not necessarily address all potential threats to our competitive advantage
11. 58If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed
12. 59Our solutions contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products
13. 60We collect, process, store, share, disclose and use personal information and other data, which subjects us to governmental regulations and other legal obligations related to privacy and security, and our actual or perceived failure to comply with such obligations could harm our business
14. 61If we or our critical third-party providers experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected
15. 62We rely on on-premise, co-located and third-party data centers and platforms to host our website and other online services, as well as for research and development purposes and any interruptions of service or failures may impair and harm our business
16. 63We are subject to certain manufacturing restrictions related to licensed intellectual property rights that were developed with the financial assistance of United States government grants

Risks related to litigation and our intellectual property

1. 64We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, unsuccessful, and could interfere with our ability to develop, manufacture and commercialize our products or technologies
2. 65We are involved in lawsuits to protect, enforce or defend our patents and other intellectual property rights, which are expensive, time consuming and could ultimately be unsuccessful

Risks related to ownership of our Class A common stock

1. 66Sales of a substantial number of shares of our Class A common stock by our existing stockholders could cause the price of our Class A common stock to decline
2. 67The multi-class structure of our common stock has the effect of concentrating voting control with those stockholders who held our capital stock prior to the completion of our IPO, including our co-founders, and may depress the trading price of our Class A common stock
3. 68Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Class A common stock
4. 69We may fail to meet our publicly announced guidance or other expectations about our business, which could cause our stock price to decline
5. 70The market price of our Class A common stock may be volatile, which could result in substantial losses for investors
6. 71Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline
7. 72We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal controls over financial reporting